ストックスクリーナーアプリを入手
1.19
0.83%
-0.01
In 8 Bio Inc (INAB) 最新ニュース
BlackRock (CABA) discloses 9.6M Cabaletta Bio shares under sole control - Stock Titan
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q32 Bio Inc. (QTTB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cabaletta Bio (CABA) sees Millennium group report 2.07M-share, 1.3% ownership stake - Stock Titan
Kala Bio, Inc. Files Form 8-K with SEC Detailing Nasdaq Listing and Corporate Information - Minichart
Nuvation Bio sets Aug. 6 webcast on cancer treatment updates - Stock Titan
Belite Bio (BLTE) Leerink’s Global Healthcare Conference 2025 Summary - Quartr
Nuvation Bio (NUVB) CFO exercises 40,000 share options and boosts holdings - Stock Titan
Valion Bio (OTC: VBIO) investor group caps ownership at 9.99% with blocker - Stock Titan
Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO - Stock Titan
Entera Bio (NASDAQ: ENTX) expands share authorization and equity plan pool - Stock Titan
Bio-Path Holdings (BPTH) plans AML trial restart and crypto treasury - Stock Titan
Q32 Bio Enters Underwriting for $18.25 Offering, Net Proceeds ~$188M; Option Lifts to ~$216M - TradingView
Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant deal - Stock Titan
Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B - Stock Titan
Valion Bio reports 200-fold Entolimod scale-up, advances govt engagement and oncology plans - TradingView
Valion Bio (OTC: VBIO) details biodefense and oncology plans - Stock Titan
Q32 Bio (QTTB) shows Phase 2a alopecia areata responses with bempikibart - Stock Titan
[8-K] Q32 Bio Inc. Reports Material Event - Stock Titan
Experimental alopecia areata drug sees 40% of patients hit key hair regrowth mark - Stock Titan
Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level? - Yahoo Finance
Gossamer Bio (GOSS) Proxy filing Summary - Quartr
Palisade Bio (PALI) director adds 45,000 shares through July open-market buys - Stock Titan
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled - TradingView
Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s study - Stock Titan
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma - GlobeNewswire Inc.
Kevin Tang’s Tang Capital buys $141,864 in Boundless Bio (BOLD) By Investing.com - Investing.com India
Form 4 Boundless Bio Inc For: 8 July By Investing.com - Investing.com Canada
Ten percent owner of Boundless Bio (NASDAQ: BOLD) adds shares - Stock Titan
Form 4 Palisade Bio Inc For: 8 July By Investing.com - Investing.com Nigeria
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy - Morningstar
Gossamer Bio (GOSS) Q1 2025 earnings summary - Quartr
BIO-key Regains Nasdaq Compliance; Trading to Resume July 8 - TradingView
Inmune Bio (NASDAQ: INMB) director exercises 14,801 warrants at $1.40 - Stock Titan
INmune Bio (INMB) CSO exercises April 2024 warrants and extends remaining term - Stock Titan
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - GlobeNewswire
Passage BIO (NASDAQ: PASG) holder Lynx1 reports 21% ownership amid Remix deal - Stock Titan
Climb Bio, Inc. Files Form 8-K: Key Company Information, NASDAQ Listing, and Emerging Growth Status - Minichart
D.E. Shaw discloses 8.3% Gossamer Bio (GOSS) ownership stake - Stock Titan
Breanna O’Reilly joins Climb Bio (NASDAQ: CLYM) board with stock option grant - Stock Titan
Gossamer Bio (NASDAQ: GOSS) sets note conversion rate and warrant exercise price - Stock Titan
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027 - TradingView
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
Avai Bio (AVAI) notifies SEC of late FY2026 10-K, cites financial compilation - Stock Titan
Tang-linked entities report 11.3% stake in Boundless Bio (NASDAQ: BOLD) - Stock Titan
GRI Bio Inc. (GRI) Declines Over 8%, Approaching Critical Support at $1.73Liquidity Order Flow - dars.gov.et
KALA BIO, Inc. SEC Filing (Jun 26, 2026) - Stock Titan
Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership - Stock Titan
CABA Forecast — Price Target — Prediction for 2027 - TradingView
INmune Bio clears key UK pediatric review for Ebstrocel in RDEB - Stock Titan
Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing - TradingView
Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M - Stock Titan
Passage Bio (PASG) to combine with Remix; Remix valued at $226M, $100M raise - Stock Titan
[144] Nuvation Bio Inc. SEC Filing - Stock Titan
MHRA backs INmune Bio (NASDAQ: INMB) plan for 2026 UK CORDStrom filing - Stock Titan
LeonaBio (NASDAQ: LONA) shareholders approve directors, EY auditor and executive pay cadence - Stock Titan
JPMorgan Cuts Upstream Bio Stock Target to Eight Dollars - sekbernews.id
Serapha Bio to take control of Boundless Bio (NASDAQ: BOLD) in cash-dividend merger - Stock Titan
FDA grants Orphan Drug Designation to GRI Bio (NASDAQ: GRI) therapy GRI-0621 in IPF - Stock Titan
Valion Bio (VBIO) CFO exercises 92 RSUs, holds 618 common shares after conversion - Stock Titan
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):